Skip to main content
Top
Published in: Cardiovascular Toxicology 2/2017

Open Access 01-04-2017

Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Authors: Lena Rubi, Daniel Eckert, Stefan Boehm, Karlheinz Hilber, Xaver Koenig

Published in: Cardiovascular Toxicology | Issue 2/2017

Login to get access

Abstract

Ibogaine is a plant alkaloid used as anti-addiction drug in dozens of alternative medicine clinics worldwide. Recently, alarming reports of life-threatening cardiac arrhythmias and cases of sudden death associated with the ingestion of ibogaine have accumulated. Using whole-cell patch clamp recordings, we assessed the effects of ibogaine and its main metabolite noribogaine on action potentials in human ventricular-like cardiomyocytes derived from induced pluripotent stem cells. Therapeutic concentrations of ibogaine and its long-lived active metabolite noribogaine significantly retarded action potential repolarization in human cardiomyocytes. These findings represent the first experimental proof that ibogaine application entails a cardiac arrhythmia risk for humans. In addition, they explain the clinically observed delayed incidence of cardiac adverse events several days after ibogaine intake. We conclude that therapeutic concentrations of ibogaine retard action potential repolarization in the human heart. This may give rise to a prolongation of the QT interval in the electrocardiogram and cardiac arrhythmias.
Literature
1.
go back to reference Brown, T. K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6, 3–16.CrossRefPubMed Brown, T. K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6, 3–16.CrossRefPubMed
2.
go back to reference Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57, 398–412.CrossRefPubMed Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57, 398–412.CrossRefPubMed
3.
go back to reference Vastag, B. (2005). Addiction research. Ibogaine therapy: A ‘vast, uncontrolled experiment’. Science, 308, 345–346.CrossRefPubMed Vastag, B. (2005). Addiction research. Ibogaine therapy: A ‘vast, uncontrolled experiment’. Science, 308, 345–346.CrossRefPubMed
4.
go back to reference Hoelen, D. W., Spiering, W., & Valk, G. D. (2009). Long-QT syndrome induced by the antiaddiction drug ibogaine. New England Journal of Medicine, 360, 308–309.CrossRefPubMed Hoelen, D. W., Spiering, W., & Valk, G. D. (2009). Long-QT syndrome induced by the antiaddiction drug ibogaine. New England Journal of Medicine, 360, 308–309.CrossRefPubMed
5.
go back to reference Paling, F. P., Andrews, L. M., Valk, G. D., & Blom, H. J. (2012). Life-threatening complications of ibogaine: three case reports. Netherlands Journal of Medicine, 70, 422–424.PubMed Paling, F. P., Andrews, L. M., Valk, G. D., & Blom, H. J. (2012). Life-threatening complications of ibogaine: three case reports. Netherlands Journal of Medicine, 70, 422–424.PubMed
6.
go back to reference Pleskovic, A., Gorjup, V., Brvar, M., & Kozelj, G. (2012). Ibogaine-associated ventricular tachyarrhythmias. Clinical Toxicology, 50, 157.CrossRefPubMed Pleskovic, A., Gorjup, V., Brvar, M., & Kozelj, G. (2012). Ibogaine-associated ventricular tachyarrhythmias. Clinical Toxicology, 50, 157.CrossRefPubMed
7.
go back to reference Papadodima, S. A., Dona, A., Evaggelakos, C. I., Goutas, N., & Athanaselis, S. A. (2013). Ibogaine related sudden death: A case report. Journal of Forensic and Legal Medicine, 20, 809–811.CrossRefPubMed Papadodima, S. A., Dona, A., Evaggelakos, C. I., Goutas, N., & Athanaselis, S. A. (2013). Ibogaine related sudden death: A case report. Journal of Forensic and Legal Medicine, 20, 809–811.CrossRefPubMed
8.
go back to reference Mazoyer, C., Carlier, J., Boucher, A., Peoc’h, M., Lemeur, C., & Gaillard, Y. (2013). Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. Journal of Forensic Sciences, 58, 1666–1672.CrossRefPubMed Mazoyer, C., Carlier, J., Boucher, A., Peoc’h, M., Lemeur, C., & Gaillard, Y. (2013). Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. Journal of Forensic Sciences, 58, 1666–1672.CrossRefPubMed
9.
go back to reference Jalal, S., Daher, E., & Hilu, R. (2013). A case of death due to ibogaine use for heroin addiction: Case report. The American Journal on Addictions, 22, 302.CrossRefPubMed Jalal, S., Daher, E., & Hilu, R. (2013). A case of death due to ibogaine use for heroin addiction: Case report. The American Journal on Addictions, 22, 302.CrossRefPubMed
10.
go back to reference Asua, I. (2013). Growing menace of ibogaine toxicity. British Journal of Anaesthesia, 111, 1029–1030.CrossRefPubMed Asua, I. (2013). Growing menace of ibogaine toxicity. British Journal of Anaesthesia, 111, 1029–1030.CrossRefPubMed
11.
go back to reference Vlaanderen, L., Martial, L. C., Franssen, E. J., van der Voort, P. H., Oosterwerff, E., & Somsen, G. A. (2014). Cardiac arrest after ibogaine ingestion. Clinical Toxicology, 52, 642–643.CrossRefPubMed Vlaanderen, L., Martial, L. C., Franssen, E. J., van der Voort, P. H., Oosterwerff, E., & Somsen, G. A. (2014). Cardiac arrest after ibogaine ingestion. Clinical Toxicology, 52, 642–643.CrossRefPubMed
13.
go back to reference Koenig, X., Kovar, M., Boehm, S., Sandtner, W., & Hilber, K. (2014). Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology, 19, 237–239.CrossRefPubMed Koenig, X., Kovar, M., Boehm, S., Sandtner, W., & Hilber, K. (2014). Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology, 19, 237–239.CrossRefPubMed
14.
go back to reference Koenig, X., Kovar, M., Rubi, L., Mike, A. K., Lukacs, P., Gawali, V. S., et al. (2013). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug’s cardiac ion channel profile. Toxicology and Applied Pharmacology, 273, 259–268.CrossRefPubMedPubMedCentral Koenig, X., Kovar, M., Rubi, L., Mike, A. K., Lukacs, P., Gawali, V. S., et al. (2013). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug’s cardiac ion channel profile. Toxicology and Applied Pharmacology, 273, 259–268.CrossRefPubMedPubMedCentral
15.
go back to reference Thurner, P., Gafar, H., Gawali, V. S., Kudlacek, O., Zezula, J., Hilber, K., et al. (2014). Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine. Journal of Pharmacology and Experimental Therapeutics, 348, 346–358.CrossRefPubMed Thurner, P., Gafar, H., Gawali, V. S., Kudlacek, O., Zezula, J., Hilber, K., et al. (2014). Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine. Journal of Pharmacology and Experimental Therapeutics, 348, 346–358.CrossRefPubMed
17.
go back to reference Alper, K., Bai, R., Liu, N., Fowler, S. J., Huang, X. P., Priori, S. G., & Ruan, Y. (2016). hERG blockade by Iboga alkaloids. Cardiovascular Toxicology, 16, 14–22.CrossRefPubMed Alper, K., Bai, R., Liu, N., Fowler, S. J., Huang, X. P., Priori, S. G., & Ruan, Y. (2016). hERG blockade by Iboga alkaloids. Cardiovascular Toxicology, 16, 14–22.CrossRefPubMed
18.
go back to reference Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.CrossRefPubMed Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.CrossRefPubMed
19.
go back to reference Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences, 844, 274–292.CrossRefPubMed Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences, 844, 274–292.CrossRefPubMed
20.
go back to reference Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55, 189–194.CrossRefPubMed Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55, 189–194.CrossRefPubMed
21.
go back to reference Obach, R. S., Pablo, J., & Mash, D. C. (1998). Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metabolism and Disposition, 26, 764–768.PubMed Obach, R. S., Pablo, J., & Mash, D. C. (1998). Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metabolism and Disposition, 26, 764–768.PubMed
22.
go back to reference Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn, W. L. (2001). Ibogaine in the treatment of heroin withdrawal. Alkaloids Chemistry Biology, 56, 155–171.CrossRefPubMed Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn, W. L. (2001). Ibogaine in the treatment of heroin withdrawal. Alkaloids Chemistry Biology, 56, 155–171.CrossRefPubMed
Metadata
Title
Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Authors
Lena Rubi
Daniel Eckert
Stefan Boehm
Karlheinz Hilber
Xaver Koenig
Publication date
01-04-2017
Publisher
Springer US
Published in
Cardiovascular Toxicology / Issue 2/2017
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-016-9366-y

Other articles of this Issue 2/2017

Cardiovascular Toxicology 2/2017 Go to the issue